According to QIAN Qijun, director of the Shanghai Cell Therapy Engineering Research Center, China will have at least a 20 companies or institutions to start CAR-T clinical trials soon, as many funds have been or are being flooded into the field of cellular immunotherapy. According to Founder Securities, at present there are more than 20 domestic enterprises and hospitals which participate in R&D of CAR-T cell therapy, and the number of CAR-T cell therapy clinical trials registered by domestic R & D units has reached over 100.
China Bio news release, December 22, 2017